SCINAI IMMUNOTHERAPEUTICS LT
SCNINASDAQTrading Snapshot
- Day Range
- $1.46 – $1.49
- 52-Week Range
- $1.43 – $16.30
- Volume
- $1.73B
- Avg Volume
- $2.26B
- Shares Outstanding
- 20.68B
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $467,898
- P/E Ratio
- —
- P/S Ratio
- 0.4x
- EPS (TTM)
- $-0.01
- Dividend Yield
- —
- Dilution (1yr)
- −99.0%
Why Investors Own SCNI
- ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SCINAI IMMUNOTHERAPEUTICS LT
SCNI
StockOtter · stockotter.spaceAbout SCINAI IMMUNOTHERAPEUTICS LT
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai I
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALE
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd.
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.